| Trial ID: | L0361 |
| Source ID: | NCT01350388
|
| Associated Drug: |
Febuxostat
|
| Title: |
Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01350388/results
|
| Conditions: |
Chronic Kidney Disease|Diabetes
|
| Interventions: |
DRUG: Febuxostat|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration in Adipose Tissue From Baseline to 24 Weeks, The percent difference in thiobarbituric acid reactive substance (TBARS) concentration geometric mean values from baseline to 24 weeks was calculated for each arm, Baseline and 24 weeks|Change in Adiponectin Concentration in Adipose Tissue From Baseline to 24 Weeks, The percent difference in adiponectin concentration geometric mean values from baseline to 24 weeks was calculated for each arm, Baseline and 24 weeks|Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1) From Baseline to 24 Weeks, The percent difference in TGF-beta1 concentration geometric mean values from baseline to 24 weeks was calculated for each arm, Baseline and 24 weeks | Secondary: Change in Tumor Necrosis Factor-α (TNF-α) Concentration in Plasma From Baseline to 24 Weeks, The percent difference in plasma TNF-α concentration geometric mean values from baseline to 24 weeks was calculated for each arm, Baseline and 24 weeks|Change in Interleukin-6 (IL-6) Concentration in Plasma From Baseline to 24 Weeks, The percent difference in plasma IL-6 concentration geometric mean values from baseline to 24 weeks was calculated for each arm, Baseline and 24 weeks|Change in High Sensitivity C-Reactive Protein (hsCRP) Concentration in Plasma From Baseline to 24 Weeks, The percent difference in plasma hsCRP concentration geometric mean values from baseline to 24 weeks was calculated for each arm, Baseline and 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Utah | Collaborators: Takeda
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2011-05
|
| Completion Date: |
2013-12
|
| Results First Posted: |
2016-10-03
|
| Last Update Posted: |
2016-10-03
|
| Locations: |
University of Utah, Salt Lake City, Utah, 84112, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01350388
|
